ALAN is involved in task 6.2 of MEET-AML (Metabolic vulnerabilities for personalized therapeutic approaches in acute myeloid leukemia) study.
The main objective of the study is to develop a model of personalized medicine that integrates the disease phenotype, therapeutic opportunities and patients’ preferences, that can be used for patient’s management.
To accomplish the main objective, the following actions will be undertaken:
(i) to identify metabolic vulnerabilities in AML patients;
(ii) to integrate genomic, transcriptomic, metabolic, proteomic and drug screening data in order to define AML phenotypic profiles and personalized therapeutic approaches targeting leukemic cell metabolism;
(iii) to evaluate leukemia patients’ preferences towards benefits and risks associated with different treatment options as well as capture their perspective towards this multi-omics approach.
Task 6.2 – Patient perspective
This task will elicit and analyze leukemia patients’ preferences towards benefits and risks associated with different treatment option as well as their preferences towards the omics-approach. ALAN is involved in the design and evaluation of patient perspective analysis and in the dissemination activities.